Patents by Inventor Alena Donda

Alena Donda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Targeted CD1d molecules
    Patent number: 9809654
    Abstract: The invention is directed to a compound comprising one or more CD1d complexes in association with an antibody specific for a cell surface marker. The CD1d complexes comprise a CD1d, a ?2-microglobulin molecule, and may further comprise an antigen bound to the CD1d binding groove. The invention is further directed to methods of inhibiting or stimulating an immune response with the CD1d-antibody compounds, in particular anti-tumor and autoimmunity responses.
    Type: Grant
    Filed: September 26, 2003
    Date of Patent: November 7, 2017
    Assignee: Vaccinex, Inc.
    Inventors: Bruno Robert, Alena Donda, Valerie Cesson, Jean-Pierre Mach, Maurice Zauderer
  • MODULATION OF NKT CELL ACTIVITY WITH ANTIGEN-LOADED CD1d MOLECULES
    Publication number: 20170312356
    Abstract: The invention is directed to methods of modulating an immune response in an animal, comprising administering a composition comprising one or more soluble CD1d complexes, in particular non-specific soluble CD1d complexes. Soluble CD1d complexes comprise a soluble CD1d polypeptide, a ?2-microglobulin polypeptide, and a ceramide-like glycolipid antigen bound to the CD1d antigen binding groove, and in certain embodiments, an immunogen. The administration of compositions of the present invention affects the activity of CD1d-restricted NKT cells, and in particular, allows for multiple administrations without causing CD1d-restricted NKT cell anergy.
    Type: Application
    Filed: February 8, 2017
    Publication date: November 2, 2017
    Applicant: VACCINEX, INC.
    Inventors: Alena DONDA, Jean-Pierre MACH, Kathrin STIRNEMANN, Maurice Zauderer
  • Modulation of NKT cell activity with antigen-loaded CD1d molecules
    Patent number: 9603922
    Abstract: The invention is directed to methods of modulating an immune response in an animal, comprising administering a composition comprising one or more soluble CD1d complexes, in particular non-specific soluble CD1d complexes. Soluble CD1d complexes comprise a soluble CD1d polypeptide, a ?2-microglobulin polypeptide, and a ceramide-like glycolipid antigen bound to the CD1d antigen binding groove, and in certain embodiments, an immunogen. The administration of compositions of the present invention affects the activity of CD1d-restricted NKT cells, and in particular, allows for multiple administrations without causing CD1d-restricted NKT cell anergy.
    Type: Grant
    Filed: February 21, 2008
    Date of Patent: March 28, 2017
    Assignee: VACCINEX, INC.
    Inventors: Alena Donda, Jean-Pierre Mach, Kathrin Stirnemann
  • Modulation of NKT Cell Activity with Antigen-Loaded CD1d Molecules
    Publication number: 20080254045
    Abstract: The invention is directed to methods of modulating an immune response in an animal, comprising administering a composition comprising one or more soluble CD1d complexes, in particular non-specific soluble CD1d complexes. Soluble CD1d complexes comprise a soluble CD1d polypeptide, a ?2-microglobulin polypeptide, and a ceramide-like glycolipid antigen bound to the CD1d antigen binding groove, and in certain embodiments, an immunogen. The administration of compositions of the present invention affects the activity of CD1d-restricted NKT cells, and in particular, allows for multiple administrations without causing CD1d-restricted NKT cell anergy.
    Type: Application
    Filed: February 21, 2008
    Publication date: October 16, 2008
    Inventors: Alena DONDA, Jean-Pierre MACH, Kathrin STIRNEMANN, Maurice ZAUDERER
  • Multicomponent conjugates which bind to target molecules and stimulate T cell lysis
    Publication number: 20070237771
    Abstract: The invention relates to immunoconjugates of formula: A-B—(C)n where B may be present or absent, A is a specific binding protein such as an antibody or an antibody binding fragment, or a ligand binding to a receptor present on target cells B comprises at least one molecule to which “A” and “C” bind, such as an avidin/streptavidin complex, “C” is an MHC molecule, and “n” is a whole number ranging from 1 to 10. The conjugates provide the exquisite binding specificity of antibodies, combined with an ability to stimulate cytotoxic T cells to identify and to destroy cells on which the conjugate is bound and oligomerized. The conjugates are useful both therapeutically and diagnostically.
    Type: Application
    Filed: May 21, 2007
    Publication date: October 11, 2007
    Inventors: Alena Donda, Jean-Pierre Mach, Valerie Cesson, Bruno Robert, Pedro Romero, Immanuel Leuscher, Philippe Guillaume
  • Targeted cd1d molecules
    Publication number: 20060269540
    Abstract: The invention is directed to a compound comprising one or more CD1d complexes in association with an antibody specific for a cell surface marker. The CD1d complexes comprise a CD1d, a ?2-microglobulin molecule, and may further comprise an antigen bound to the CD1d binding groove. The invention is further directed to methods of inhibiting or stimulating an immune response with the CD1d-antibody compounds, in particular anti-tumor and autoimmunity responses.
    Type: Application
    Filed: September 26, 2003
    Publication date: November 30, 2006
    Applicant: Vaccinex, Inc.
    Inventors: Bruno Robert, Alena Donda, Valerie Cesson, Jean-Pierre Mach, Maurice Zauderer
  • Multicomponent conjugates which bind to target molecules and stimulate T cell lysis
    Publication number: 20040143094
    Abstract: The invention relates to immunoconjugates of formula:
    Type: Application
    Filed: August 1, 2003
    Publication date: July 22, 2004
    Inventors: Alena Donda, Jean-Pierre Mach, Valerie Cesson, Bruno Robert, Pedro Romero, Immanuel Leuscher, Philippe Guillaume